What Is the Safest Weight Loss Surgery? Evidence (Mortality, Complications)

The short answer: laparoscopic sleeve gastrectomy has the lowest 30-day mortality (~0.08%) and the lowest early-complication burden of any modern bariatric procedure with durable weight-loss efficacy^[4][6]. Roux-en-Y gastric bypass (RYGB) sits at ~0.14% with slightly better long-term diabetes remission^[1][2]. Adjustable gastric band is the lowest- complication procedure but has unacceptable long-term revision rates. The single biggest safety lever is operating at an MBSAQIP-accredited center with a high-volume surgeon. This article is informational; bariatric procedure selection must be made with an ASMBS-credentialed surgeon.

At a glance

• Sleeve gastrectomy: ~0.08% 30-day mortality. Lowest among modern durable-efficacy bariatric procedures. Approximately 60-65% of all US bariatric procedures. Berger 2016 (Ann Surg)^[4] is the foundational MBSAQIP registry paper.
• Roux-en-Y gastric bypass: ~0.14% 30-day mortality. Slightly higher early risk; slightly better diabetes remission and weight-loss durability at 5 years (Salminen 2018 SLEEVEPASS^[1], Schauer 2017 STAMPEDE^[2]).
• BPD/DS and SADI-S: ~0.8-1.0% 30-day mortality. Highest mortality but largest weight loss (typically 35-40% TBWL). Reserved for super-obese (BMI ≥50) or revisional cases.
• Adjustable gastric band: lowest 30-day mortality (<0.05%) but worst long-term outcomes. 40-50% band removal within 10 years; rarely performed in 2026.
• GLP-1 medications: essentially zero treatment- attributable mortality. But −14.9% TBWL on semaglutide^[7] vs −20.9% on tirzepatide^[8] vs −25 to −35% with surgery. Magnitude trade-off.
• 2022 ASMBS/IFSO threshold: BMI ≥35 alone or BMI ≥30 + metabolic comorbidity. Eisenberg 2022 (Surg Obes Relat Dis)^[3] is the current consensus statement.
• Volume + accreditation matter more than procedure. An MBSAQIP-accredited high-volume center reduces 30-day mortality more than the procedure choice for most patients.

The bariatric procedure landscape in 2026

Five procedures account for essentially all metabolic and bariatric surgery performed in the United States today. Understanding each in mechanism, magnitude, and risk profile is the starting point for any safety discussion.

• Laparoscopic sleeve gastrectomy (LSG). Approximately 80% of the stomach (the greater-curvature fundus and body) is resected, leaving a banana-shaped gastric tube. No intestinal rerouting. Mechanism: restrictive plus hormonal (ghrelin reduction). Currently approximately 60-65% of US bariatric procedures.
• Laparoscopic Roux-en-Y gastric bypass (RYGB). A small (~30 mL) gastric pouch is created; the small intestine is divided and a Roux limb is anastomosed to the pouch, bypassing the duodenum and proximal jejunum. Mechanism: restrictive plus malabsorptive plus hormonal. Approximately 25-30% of US bariatric procedures.
• Adjustable gastric band (LAGB / LAP-BAND). An inflatable silicone band is placed around the upper stomach; a subcutaneous port allows adjustment of band tightness. Mechanism: pure restriction. Fewer than 1% of modern procedures.
• Biliopancreatic diversion with duodenal switch (BPD/DS). Combines a sleeve gastrectomy with a significant intestinal bypass (long Roux and biliopancreatic limbs). Mechanism: restrictive plus aggressive malabsorption. Highest weight loss; highest nutritional deficiency risk. Approximately 1-2% of procedures.
• Single-anastomosis duodeno-ileal bypass with sleeve (SADI-S). A simpler variant of BPD/DS with a single intestinal anastomosis. Newer procedure; emerging evidence. Approximately 1-3% of procedures.

For broader context on whether surgery is the right call versus continued GLP-1 therapy, see our bariatric surgery vs GLP-1 decision guide.

30-day mortality: the MBSAQIP national registry data

The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) is a joint American College of Surgeons / ASMBS program that prospectively collects 30-day outcomes data from approximately 800 accredited US bariatric centers. It is the most rigorous outcomes registry in bariatric surgery and the data source for the mortality figures most commonly cited.

Berger and colleagues 2016 (Ann Surg)^[4] reported the first MBSAQIP-derived analysis of laparoscopic sleeve gastrectomy outcomes. Across the national cohort, 30-day mortality after laparoscopic sleeve gastrectomy was approximately 0.08-0.10%. Subsequent MBSAQIP analyses by Daigle 2018 (Surg Obes Relat Dis)^[5] prioritized which complications drive 30-day mortality and readmission, identifying anastomotic leak, bleed, venous thromboembolism, and unplanned reoperation as the dominant drivers.

Pooling across MBSAQIP analyses and major center series:

• Laparoscopic sleeve gastrectomy: 30-day mortality approximately 0.08-0.10%. Leak rate approximately 1-2%. Bleed rate approximately 1-2%. Readmission approximately 5%.
• Laparoscopic Roux-en-Y gastric bypass: 30-day mortality approximately 0.14-0.20%. Leak rate approximately 1-2%. Bleed rate approximately 1-3%. Readmission approximately 6-8%.
• Biliopancreatic diversion with duodenal switch: 30-day mortality approximately 0.8-1.0%. Higher complication burden across all categories.
• Adjustable gastric band: 30-day mortality approximately <0.05%. Very low early complication burden; the long-term picture is the problem.

For perspective, 30-day mortality after laparoscopic cholecystectomy (a common elective abdominal procedure) is approximately 0.15-0.5%, and 30-day mortality after total hip arthroplasty is approximately 0.3-0.5%. Modern sleeve gastrectomy and RYGB are at the lower end of, or below, common elective surgical risk.

SLEEVEPASS: the head-to-head 5-year RCT

Salminen and colleagues 2018 (JAMA)^[1] reported the 5-year outcomes of the SLEEVEPASS randomized clinical trial — 240 patients with morbid obesity randomized to laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass at three Finnish bariatric centers.

Key 5-year findings:

• Weight loss. Both procedures produced substantial and durable weight loss. RYGB produced slightly greater %EWL (excess weight loss) at 5 years, but the difference did not reach the pre-specified threshold for equivalence in some primary analyses. Sleeve produced approximately 49% EWL at 5 years; RYGB approximately 57% EWL.
• Type 2 diabetes remission. Both procedures produced high rates of diabetes remission. RYGB had a modestly higher remission rate (37% complete remission) than sleeve (25%) at 5 years.
• Quality of life. Similar improvements in both arms on the validated instruments used.
• Late complications. Sleeve patients had more reflux symptoms; RYGB patients had more late complications overall including marginal ulcer and internal hernia.

The SLEEVEPASS take-away for the “safest surgery” question: sleeve and RYGB are both safe and effective. Sleeve has lower short-term complications and similar but slightly lower weight loss; RYGB has slightly better diabetes remission and slightly higher late-complication burden.

STAMPEDE: surgery vs medical therapy for diabetes

Schauer and colleagues 2017 (NEJM, STAMPEDE 5-year)^[2] reported the 5-year outcomes of 150 patients with type 2 diabetes and BMI 27-43 randomized to intensive medical therapy alone, intensive medical therapy plus sleeve gastrectomy, or intensive medical therapy plus RYGB.

Key 5-year findings: both surgical arms produced significantly greater reductions in HbA1c (target ≤6.0%), weight, and medication burden than medical therapy alone. RYGB patients achieved the target HbA1c slightly more often than sleeve patients (29% vs 23% vs 5% for medical therapy alone), but both surgeries were dramatically superior to medical therapy on every endpoint. Mortality across the three arms was low and not significantly different.

STAMPEDE established the modern evidence base for metabolic surgery (as opposed to weight-loss surgery) — that is, the use of bariatric procedures specifically to treat type 2 diabetes in patients with lower BMI thresholds. It directly supports the 2022 ASMBS/IFSO lowering of the BMI threshold to ≥30 in patients with metabolic disease.

Long-term safety: Howard 2021 5-year cohort

Howard, Chao, Yang, Thumma, Chhabra and colleagues 2021 (JAMA Surg)^[6] compared 5-year safety endpoints between sleeve gastrectomy and RYGB in a large US cohort of patients with severe obesity. The endpoints were subsequent operations, interventions, hospitalizations, and emergency department visits.

Key findings at 5 years:

• Subsequent operations. Sleeve patients had lower rates of subsequent abdominal operations than RYGB patients.
• Hospitalizations. Sleeve patients had lower rates of all-cause hospitalization in the 5-year window.
• Endoscopic interventions. Sleeve patients had higher rates of endoscopy (largely driven by reflux evaluation and stricture management); RYGB patients had higher rates of small bowel obstruction interventions (internal hernias).
• Nutritional and ulcer complications. RYGB patients had higher rates of marginal ulcer and nutritional deficiency presentations.

The Howard 2021 picture: sleeve is the lower-burden procedure long-term across most safety endpoints, with reflux being the notable trade-off. This complements the SLEEVEPASS short- and mid-term picture: sleeve has the lower lifetime complication burden, and RYGB has the slight efficacy edge in diabetes-dominant patients.

Long-term complications by procedure

Every bariatric procedure has its characteristic late complication profile. Understanding these is part of the safety calculus, not just the 30-day window.

• Sleeve gastrectomy. Gastroesophageal reflux disease (GERD) develops or worsens in approximately 20-30% of patients. Approximately 3-5% require conversion to RYGB for refractory reflux. Staple-line leak (early, typically <30 days) approximately 1-2%; can be devastating when it occurs. Nutritional deficiencies are less severe than RYGB but still require lifelong multivitamin, B12, and iron supplementation.
• Roux-en-Y gastric bypass. Marginal ulcer at the gastrojejunal anastomosis (3-5%, higher in smokers and NSAID users). Internal hernia through the mesenteric defects (1-3%) — can present years post-op and requires urgent surgical management. Dumping syndrome (early or late, 10-50% of patients depending on definition). Nutritional deficiencies including iron, vitamin B12, vitamin D, calcium, and thiamine requiring lifelong supplementation and annual labs.
• Adjustable gastric band. Slippage (band migration), erosion (band into stomach wall), port infection or malposition, esophageal dilation from chronic obstruction. 40-50% band removal within 10 years in long-term cohorts.
• BPD/DS and SADI-S. Severe nutritional deficiencies — fat-soluble vitamin deficiencies (A, D, E, K), protein-calorie malnutrition, copper and zinc deficiency — requiring intensive lifelong monitoring. Steatorrhea and frequent loose stools are common.

GLP-1 medications: the non-surgical alternative

Semaglutide (Wegovy / Ozempic) and tirzepatide (Zepbound / Mounjaro) have changed the “safest weight-loss intervention” calculation entirely. They have essentially zero treatment-attributable mortality in their pivotal trials, no surgical complications, and produce clinically significant weight loss in most patients.

Magnitude bounds from the pivotal trials:

• STEP-1 semaglutide 2.4 mg weekly (Wilding 2021)^[7]: −14.9% body weight at 68 weeks vs −2.4% with placebo. Lifestyle counseling in both arms.
• SURMOUNT-1 tirzepatide 15 mg weekly (Jastreboff 2022)^[8]: −20.9% body weight at 72 weeks vs −3.1% with placebo. Lifestyle counseling in both arms.
• Bariatric surgery typical TBWL: −25 to −35% at 12-24 months across sleeve and RYGB; up to −40% with BPD/DS.

The trade-offs of GLP-1 therapy versus surgery: GLP-1s require indefinite ongoing therapy (weight regain on discontinuation is substantial), cost approximately $1,000- $1,400 per month at list price and approximately $300-$600 per month with insurance or compounded versions, and produce meaningful but smaller weight loss than surgery. Surgery is a one-time intervention with one-time cost but carries surgical risk and is irreversible (especially sleeve and BPD/DS). For most patients with BMI 35-45 and good GLP-1 response, the 2026 calculus increasingly favors continued GLP-1 therapy. For patients with BMI >45 or insufficient GLP-1 response or severe metabolic disease, surgery remains the higher-magnitude option.

Combining bariatric surgery and GLP-1 therapy

Two combination strategies are now common at bariatric centers:

• Sleeve + GLP-1 from the start. A primary sleeve gastrectomy (lower surgical risk than RYGB) plus ongoing GLP-1 therapy can push total TBWL into the −30 to −40% range with lower surgical risk than RYGB. This is the emerging “optimal safety + magnitude” combination for many candidates.
• GLP-1 for post-surgery weight regain. 5-10 years post-sleeve or post-RYGB, approximately 20-40% of patients experience clinically significant weight regain. Adding semaglutide or tirzepatide for regain is well-tolerated and effective, and avoids the risk of revisional surgery (which has higher complication rates than primary procedures).
• Revisional sleeve to RYGB. For refractory reflux after sleeve, conversion to RYGB resolves reflux in approximately 80% of patients. Revisional surgery has higher complication rates than primary surgery (leak rate approximately 3-5% vs 1-2%), so this decision must be made carefully with a high-volume revisional surgeon.

Peri-operative GLP-1 management is now standard. Current ASA guidance recommends holding semaglutide and tirzepatide for at least 1 week pre-operatively because of delayed gastric emptying and aspiration risk under general anesthesia. See our GLP-1 side effects Q&A for current peri-operative protocols.

Candidacy: the 2022 ASMBS/IFSO indications

Eisenberg and colleagues 2022 (Surg Obes Relat Dis)^[3] is the current consensus statement from the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders. It lowered the BMI threshold from the previous 1991 NIH consensus.

Current ASMBS/IFSO indications:

• BMI ≥35 alone (regardless of comorbidity) — sufficient indication for metabolic and bariatric surgery.
• BMI ≥30 with metabolic disease — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease — sufficient indication.
• Adolescents. Bariatric surgery may be considered in adolescents at BMI ≥35 with major comorbidity or ≥40 without, after appropriate evaluation at a center with pediatric bariatric expertise.

The cautions: insurance pre-authorization in 2026 often still uses the older 1991 NIH thresholds (BMI ≥40 alone or ≥35 with comorbidity), creating gaps between clinical eligibility and coverage. Most insurers require a 3-6 month documented medically supervised weight management program plus a bariatric psychological evaluation. For a detailed cost framing including self-pay, insurance, and Medicare pathways, see our how much is weight loss surgery evidence review and our bariatric surgery eligibility checker for a quick self-assessment.

How to find a safe bariatric surgeon

The single largest predictor of bariatric surgical safety outside of the procedure itself is center and surgeon volume. National registry analyses consistently show that high-volume centers and high-volume surgeons have lower 30-day mortality, lower leak rates, and lower readmission rates than low-volume centers, even after risk adjustment.

A safe-surgeon checklist:

• MBSAQIP accreditation. Verify center accreditation via the American College of Surgeons MBSAQIP public directory. Accreditation requires meeting structural, process, and outcomes standards audited annually.
• Surgeon volume ≥100 cases per year. Most published volume-outcome analyses use 50-100 cases per year as a threshold for “high volume”.
• Board certification + ASMBS membership. Board-certified in general surgery; member of the American Society for Metabolic and Bariatric Surgery.
• Multidisciplinary team. Registered dietitian, behavioral health specialist, bariatric nurse coordinator, and a structured pre-operative education program.
• Transparent outcomes data. Ask the center for their leak rate, mortality rate, and readmission rate. MBSAQIP-accredited centers track these prospectively.
• Long-term follow-up program. Annual labs, nutritional monitoring, weight-regain intervention pathways including GLP-1 adjuncts.

What to ask at a bariatric consultation

• What is your center’s 30-day mortality rate and how does it compare to the MBSAQIP national mean?
• What is your personal annual case volume of sleeve gastrectomy and RYGB?
• What is your center’s anastomotic / staple-line leak rate and unplanned readmission rate?
• Given my comorbidity profile (diabetes, reflux, sleep apnea, etc.), which procedure do you recommend and why?
• What is your protocol for peri-operative GLP-1 management and post-operative GLP-1 adjuncts for weight regain?
• What is the structure of long-term follow-up, including nutritional monitoring and behavioral health support?
• What is the all-in self-pay cost, and what is your pre-authorization protocol for my specific insurer?
• Have you ever performed revisional surgery for the procedure you are recommending, and what is your institution’s revisional volume and outcomes?

Magnitude check: weight loss by intervention

The chart frames the trade-off. GLP-1s give you ~15-21% TBWL with essentially zero treatment-attributable mortality. Sleeve gives you ~25% TBWL with ~0.08% 30-day mortality. RYGB gives you ~30% TBWL with ~0.14% mortality. BPD/DS gives you ~38% TBWL with ~1% mortality. The “safest surgery” question is really “which point on this curve is right for me?” — a question for a bariatric surgeon, not the internet.

Reality check: what a careful decision looks like

For a 45-year-old patient with BMI 42, type 2 diabetes on metformin, hypertension, and mild reflux:

• Step 1. Trial of tirzepatide titrated to maximum tolerated dose over 6-12 months with structured lifestyle support and the bariatric eligibility self-assessment to anchor the conversation.
• Step 2. If <10% TBWL after 12 months on maximum tolerated dose, or weight regain on discontinuation, schedule consultation at an MBSAQIP- accredited center.
• Step 3. Bariatric consultation with gastroenterology evaluation of reflux (sleeve worsens reflux; RYGB resolves it). Multidisciplinary evaluation (dietitian, behavioral health, anesthesia).
• Step 4. Procedure selection based on comorbidity profile, surgeon volume, and patient preference. For this patient with reflux + diabetes, RYGB would typically be favored over sleeve.
• Step 5. Peri-operative GLP-1 hold (1+ week pre-op per current ASA guidance), surgery at high- volume center, structured post-op follow-up with nutritional monitoring and weight-regain pathway.

For a 30-year-old patient with BMI 33 and obstructive sleep apnea but no diabetes, the same framework typically lands on continued GLP-1 therapy rather than surgery, unless GLP-1 response is inadequate or therapy cannot be maintained. For surgical loose-skin sequelae after substantial weight loss (whether surgical or pharmacologic), see our how to tighten loose skin after weight loss evidence review.

What this article is not

This article is informational, not medical advice. The choice of bariatric procedure — or whether to have surgery at all — must be made with an ASMBS-credentialed bariatric surgeon who has reviewed your individual medical history, imaging, laboratory results, and comorbidities. Use this article to prepare informed questions for that consultation, not as a substitute for it. The American Society for Metabolic and Bariatric Surgery patient resource directory is the canonical starting point for finding an MBSAQIP-accredited center.

FAQs

What is the safest form of weight loss surgery?

Laparoscopic sleeve gastrectomy has the lowest 30-day mortality of any modern bariatric procedure performed today — approximately 0.08% in national MBSAQIP registry data^[4] — and the lowest early complication burden in head-to-head trials (Salminen 2018 SLEEVEPASS^[1], Howard 2021 JAMA Surg^[6]). Adjustable gastric band has even lower complications but is rarely performed in 2026 because of poor durable weight-loss outcomes and high revision rates. The single most important safety factor is not the procedure itself but operating at an MBSAQIP-accredited center with a high-volume surgeon. This is not medical advice; bariatric procedure selection should be made with an ASMBS-credentialed surgeon who has reviewed your individual comorbidities.

What is the 30-day mortality of bariatric surgery?

Across the MBSAQIP national registry, 30-day mortality after laparoscopic sleeve gastrectomy is approximately 0.08-0.10%, Roux-en-Y gastric bypass approximately 0.14-0.20%, and biliopancreatic diversion with duodenal switch (BPD/DS) approximately 0.8-1.0%. For perspective, 30-day mortality after laparoscopic cholecystectomy (gallbladder removal) is approximately 0.15-0.5%, so modern sleeve gastrectomy has mortality similar to or lower than common elective abdominal procedures. Berger 2016 (Ann Surg)^[4] and Daigle 2018 (Surg Obes Relat Dis)^[5] are the foundational MBSAQIP papers documenting these rates.

Is sleeve gastrectomy safer than gastric bypass?

Short-term, yes — sleeve gastrectomy has lower 30-day mortality, fewer early complications, shorter operating time, and shorter hospital stay than Roux-en-Y gastric bypass in national registry data. Long-term safety is more mixed. Howard 2021 (JAMA Surg)^[6] found at 5 years, sleeve patients had fewer subsequent operations, fewer interventions, and fewer hospitalizations than RYGB patients. RYGB has higher rates of marginal ulcers, internal hernias, and nutritional deficiencies long-term. RYGB has slightly better weight loss durability and better diabetes remission at 5 years (Salminen 2018^[1], Schauer 2017 STAMPEDE^[2]). The choice depends on individual comorbidity profile.

Is gastric band still considered safe?

Adjustable gastric band (LAP-BAND) has the lowest 30-day mortality of any bariatric procedure — well below 0.05% — and was historically marketed as the safest option. However, long-term outcomes are poor: 40-50% of patients require band removal within 10 years due to slippage, erosion, esophageal dilation, or inadequate weight loss. As a result, gastric band accounted for fewer than 1% of US bariatric procedures in recent ASMBS reports. Most major centers no longer offer it as a primary procedure. The short-term safety advantage is overwhelmed by the long-term revision and re-operation burden.

Are GLP-1 medications safer than weight loss surgery?

Yes for the short-term mortality endpoint — semaglutide (Wegovy, STEP-1^[7]) and tirzepatide (Zepbound, SURMOUNT-1^[8]) have essentially zero treatment- attributable mortality in their pivotal trials versus approximately 0.08-0.20% 30-day mortality for sleeve or RYGB. GLP-1s also avoid surgical complications such as leaks, bleeds, marginal ulcers, internal hernias, and nutritional deficiencies. The trade-off is magnitude: STEP-1 semaglutide produces approximately −14.9% TBWL at 68 weeks and SURMOUNT-1 tirzepatide approximately −20.9% TBWL at 72 weeks, versus −25 to −35% TBWL with sleeve or RYGB. Weight regain on stopping GLP-1s is also substantial.

What is the BMI threshold for weight loss surgery in 2026?

The current consensus is the 2022 ASMBS/IFSO indications statement (Eisenberg 2022, Surg Obes Relat Dis)^[3], which recommends metabolic and bariatric surgery for adults with BMI ≥35 regardless of comorbidities, or BMI ≥30 with metabolic disease (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea). This lowered the threshold from the previous 1991 NIH consensus (BMI ≥40 alone or ≥35 with comorbidity). Individual insurer policies may still use the older 1991 threshold for prior authorization, which can create gaps between clinical eligibility and coverage.

Can I combine bariatric surgery with GLP-1 medications?

Yes, and this is becoming standard practice at many bariatric centers. The two main scenarios: (1) sleeve gastrectomy plus GLP-1 to push total weight loss into the −30 to −40% TBWL range with lower surgical risk than RYGB; (2) GLP-1 added after sleeve or RYGB for weight regain or insufficient response. Discontinuation of GLP-1 around the operation is typically required to reduce aspiration risk under anesthesia — current ASA guidance suggests holding semaglutide and tirzepatide for at least 1 week pre-operatively. See our GLP-1 surgical anesthesia guidance article for current peri-operative protocols.

What are the long-term complications of weight loss surgery?

Long-term complications depend on the procedure. Sleeve gastrectomy: gastroesophageal reflux disease (GERD) develops or worsens in approximately 20-30% of patients; smaller risk of staple-line leak (typically in the first 30 days). Roux-en-Y gastric bypass: marginal ulcer (3-5%), internal hernia (1-3%), dumping syndrome (10-50%), nutritional deficiencies in iron, vitamin B12, vitamin D, calcium, and thiamine requiring lifelong supplementation. BPD/DS: severe nutritional deficiencies (protein-calorie malnutrition, fat-soluble vitamin deficiencies) requiring intensive lifelong monitoring. Gastric band: slippage, erosion, port infection, esophageal dilation.

How do I find a safe bariatric surgeon?

Look for: (1) an MBSAQIP-accredited center (the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program is a joint American College of Surgeons / ASMBS program that audits center-level outcomes); (2) a surgeon board-certified in general surgery with ASMBS membership; (3) an annual case volume of at least 100 bariatric procedures (volume is one of the strongest predictors of safety in the published literature); (4) transparent center-level outcomes data; and (5) a multidisciplinary team including dietitian, behavioral health, and bariatric nurse coordinator. Use the ASMBS patient resource directory to verify accreditation status before consultation.

Should I have weight loss surgery if I can lose weight on GLP-1s?

This is the central 2026 decision and there is no universally correct answer. Factors favoring continued GLP-1 therapy: lower starting BMI (under approximately 40), good response on titration, tolerable side effects, ability to afford long-term therapy, and willingness to remain on medication indefinitely. Factors favoring surgical referral: higher starting BMI (>45), inadequate response after 12 months on maximum tolerated GLP-1 dose, severe metabolic disease requiring durable remission, inability to afford or access long-term GLP-1 therapy, or significant comorbidities for which surgery has demonstrated mortality reduction. This is exactly the conversation to have with a bariatric surgeon and your primary care physician.